| OHI | Occupational Health Institute; operative hypertension indicator; oral hygiene index; Oral Hygiene In... |
|---|---|
| EARR | extended aortic root replacement |
| EBCDIC | Extended Binary Coded Decimal Interchange Code |
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
| ECF | effective capillary flow; eosinophilic chemotactic factor; erythroid colony formation; extended care... |
| msh release-inhibiting hormone | <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh). Chemical name: Melanostatin (12 Dec 1998) |
|---|---|
| control release suture | Eyeless suture with thread attached to needle such that the two separate when tension is applied to the thread. (05 Mar 2000) |
| prolactin release-inhibiting hormone | <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin. Chemical name: Prolactin release-inhibiting factor (12 Dec 1998) |
| histamine release | The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. (12 Dec 1998) |
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| somatotropin release-inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| deliberate release | Generally refers to putting a genetically manipulated organism into field trials. (14 Nov 1997) |
| sustained release tablet | A drug product formulation that provides the required dosage initially and then maintains or repeats it at desired intervals. Synonym: prolonged action tablet, repeat action tablet. (05 Mar 2000) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
| magnesia and alumina oral suspension | A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid. (05 Mar 2000) |
| pathology, oral | A dental specialty concerned with pathology of the oral cavity. (12 Dec 1998) |
| pharyngo-oral | Relating to the pharynx and the mouth; oropharyngeal. Origin: pharyngo-+ L. Os (or-), mouth (05 Mar 2000) |